Table 2.
Laboratory results on admission and treatments of COVID-19 in Suzhou.
| Normal range | Patients (n = 75) | |
|---|---|---|
| White blood cell (109/L) | 3.5–9.5 | 5.12 (1.68–17.60) |
| Increased | 4 (5.3%) | |
| Decreased | 16 (21.3%) | |
| Lymphocyte (109/L) | 1.10–3.20 | 1.33 ± 0.63 |
| Increased | 0 | |
| Decreased | 34 (45.3%) | |
| Neutrophil (109/L) | 1.80–6.30 | 3.50 ± 2.21 |
| Increased | 4 (5.3%) | |
| Decreased | 6 (8%) | |
| NLR | 2.3 (0.6–16.0) | |
| Hemoglobin (g/L) | 130–175 | 138 ± 16 |
| Anemia (<120 g/L) | 6 (8%) | |
| Platelet (109/L) | 125–350 | 178.7 ± 66.0 |
| Increased | 1 (1.3%) | |
| Decreased | 9 (12%) | |
| Prothrombin time (s) | 10–14 | 12.2 ± 0.8 |
| Partial thromboplastin time (s) | 20–40 | 24.5 ± 3.3 |
| Fibrinogen (g/L) | 2.0–4.0 | 4.30 ± 1.19 |
| Increased | 45 (60%) | |
| Decreased | 0 | |
| D-dimer (media) | 0–550 | 210 (70–1220) |
| Increased | 9 (12%) | |
| Decreased | 0 | |
| Total bilirubin (μmol/L) | 4.0–17.1 | 9.6 (3.5–120.3) |
| Albumin (g/L) | 38–55 | 37.1 ± 4.3 |
| AST (U/L) | 8–40 | 27 (15–158) |
| ALT (U/L) | 5–40 | 40 (16–181) |
| Lactate dehydrogenase (U/L) | 135–225 | 464.5 ± 234.1 |
| Creatinine (μmol/L) | 44–106 | 64.5 ± 22.2 |
| NT-proBNP positivity (%) | <125 pg/mL | 8 (10.7%) |
| CRP positivity (%) | 0–10 mg/L | 44 (58.7%) |
| PCT positivity (%) | <0.046 ng/mL | 3 (4%) |
| Antivirus treatment | ||
| Arbidol | 42 (56%) | |
| Lopinavir/ritonavir | 46 (61.3%) | |
| Hydroxychloroquine | 6 (8%) | |
| Ribavirin | 66 (8%) | |
| Oseltamivir | 14 (18.7%) | |
| Antibiotics | 65 (86.7%) | |
| Corticosteroids | 25 (33.3%) | |
| Low molecular heparin | 16 (21.3%) | |
| Respiratory therapy | ||
| Nasal cava only | 68 (90.7%) | |
| High flow nasal cannula | 7 (9.3%) | |
| Noninvasive mechanical ventilation | 4 (5.3%) |
NLR neutrophil-to-lymphocyte ratio, AST aspartate aminotransferase, ALT alanine aminotransferase, NT-proBNP N-terminal proBNP, PCT procalcitonin.